Explore how the thalidomide tragedy and metformin delay shaped the modern FDA and European drug approval processes and the ...

Name brand GLP-1 drugs like Ozempic and Wegovy have quickly become household names, akin to Tylenol or Advil, and their rise in popularity is only increasing. Originally developed to treat type 2 ...

Researchers are investigating whether GLP-1 drugs could be used to treat addiction disorders, following patient reports of reduced cravings.

The weight you lose and the nausea you experience from GLP-1 drugs may be linked to common gene variants, but they can’t ...

GLP-1 medications like Ozempic have dominated headlines over the past couple of years. When writing his new book, Diet, Drugs and Dopamine: The New Science of Achieving a Healthy Weight, former FDA ...

In December, The Conversation hosted a webinar on AI's revolutionary role in drug discovery and development. Science and ...

DNA robots are emerging as tiny programmable machines that could one day deliver drugs, hunt viruses, and build ...

In December 2017, the FDA approved a new injectable drug to treat type 2 diabetes called semaglutide, which you likely know by its brand name: Ozempic. A few years later, during the pandemic, Wegovy, ...

The discovery of GLP-1 and its role in regulating blood glucose was a major scientific breakthrough in diabetes research, yet turning this peptide hormone into an effective medication was no easy task ...

Add Yahoo as a preferred source to see more of our stories on Google. Four-year-old Jose Morales-Ortiz, with his guardian, Keith Joyce, is taking the drug leucovorin to help with this autism symptoms.

Current federal laws that determine how marijuana and other drugs are classified have “fundamental flaws” that have done “immense damage,” according to a new analysis coauthored by a former Drug ...

Six months ago, 4-year-old Jose Morales-Ortiz was struggling to say two-word sentences. Jose has severe autism, and he couldn’t have a conversation and wouldn’t answer to his name most of the time — ...